Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

breakthrough therapy

- PMLiVE

Novartis’ targeted combination therapy recommended by NICE to treat childhood brain tumours

Gliomas are the most common type of brain cancer in paediatric patients

- PMLiVE

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

- PMLiVE

Novartis presents positive long-term data for relapsing MS treatment Kesimpta

Approximately 85% of MS patients are initially diagnosed with relapsing forms of the neurological disease

- PMLiVE

UK scientists reveal promising new treatment strategy for acute myeloid leukaemia

The aggressive form of blood cancer is responsible for more than 3,000 new cases in the UK every year

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare kidney disease IgA nephropathy

Approximately 25 people per million worldwide are diagnosed with IgAN every year

- PMLiVE

Novartis’ blood cancer therapy Kymriah recommended by NICE for routine NHS use

In England, ALL is responsible for around 300 new diagnoses every year in people aged 25 years and under

- PMLiVE

AstraZeneca shares positive three-year results for Imfinzi combination in biliary tract cancer

Approximately 210,000 people worldwide are diagnosed with the disease every year

- PMLiVE

FDA establishes new CDER centre focused on promoting clinical trial innovation

The C3TI will give internal and external parties easier access to information on clinical trial innovation

- PMLiVE

ICR scientists reveal new ways to convert inhibitor-style targeted cancer drugs into degraders

Findings from the study could help researchers create more effective treatments for cancer

- PMLiVE

Novartis gains rights to Arvinas’ prostate cancer therapy in deal worth over $1bn

The transaction also includes the sale of Arvinas’ preclinical AR-V7 programme

- PMLiVE

Novartis shares positive real-world data for Leqvio in atherosclerotic CVD

LDL-C is a causal risk factor for ASCVD and increases the risk of heart disease and stroke

- PMLiVE

BMS and Shine Cancer Support’s UK research reveals disparities in cancer diagnosis

The Cancer Equals campaign and 1,000 Voices, Not 1 report aim to help address reasons for diagnostic delays

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links